Trials in Connecticut.

This trial tested bapineuzumab, an infused antibody designed to bind and clear beta amyloid from the brain, against a placebo. It measured whether it helped…

This trial tested whether bapineuzumab, an antibody given by infusion that helps clear beta amyloid from the brain, could affect thinking and daily function in…

This Phase 2 trial tested lecanemab, an anti-amyloid antibody given by infusion, in people with early Alzheimer's disease — either mild cognitive impairment or…

This trial tested two investigational drugs, CAD106 (a vaccine-like immunotherapy targeting amyloid) and CNP520 (a small molecule targeting amyloid…

This trial tested CNP520, a drug designed to reduce amyloid buildup in the brain, against a placebo in cognitively normal older adults at elevated risk for…

This Phase 3 trial tests lecanemab, an intravenous and subcutaneous antibody drug, against placebo in people with early Alzheimer's disease — either mild…

This Phase 3 trial is testing lecanemab, an anti-amyloid antibody drug, in people who are cognitively normal but have early amyloid buildup in their brains —…

This trial tests sabirnetug, an antibody given by IV infusion every four weeks, against placebo. It looks at whether the drug slows decline in thinking and…

This Phase 3 trial tested rosiglitazone, a diabetes drug, as an add-on to standard Alzheimer's medications like Aricept in people with mild to moderate…

This trial tested whether rosiglitazone extended release, a diabetes drug, could improve thinking and memory in people already taking donepezil for mild to…

This Phase 3 trial tested rosiglitazone XR, a diabetes drug already approved for type 2 diabetes, as a standalone treatment for mild to moderate Alzheimer's…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. It looked at how well the…

This trial tested bapineuzumab, an antibody drug given by infusion, against a placebo in people with mild to moderate Alzheimer's. Researchers measured safety…

This trial looked at the long-term safety and tolerability of bapineuzumab, an antibody drug given by infusion, in people with Alzheimer's who had finished an…

Enroll-HD is an observational study, meaning no drug or treatment is given. It follows people with Huntington's disease, and their relatives and controls,…

This trial tests several investigational drugs, including gantenerumab, solanezumab, E2814 and lecanemab, against placebo. It asks whether they slow cognitive…

This Phase 3 trial tested solanezumab, an antibody drug given by IV infusion, in cognitively normal older adults who already had amyloid buildup in their…

This trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, against a placebo over two years in people with early…

This study takes a person's own bone marrow stem cells and delivers them through a vein and the lower nose. Researchers want to see whether neurologic function…

This trial tests whether aerobic exercise (like treadmill walking) does more for brain health than stretching and balance routines in older adults with mild…

This Phase 3 trial tested whether LCZ696 (sacubitril/valsartan, sold as Entresto) protects cognitive function better than valsartan alone in people with a…

This study is not testing a treatment. It is an observational study tracking how people with early-stage Alzheimer's disease or MCI use health care, what that…

This Phase 3 trial tested lanabecestat, a BACE inhibitor drug designed to reduce amyloid production in the brain, in people with early Alzheimer's dementia. It…

This trial is testing whether a single IV infusion of zoledronic acid, a bone-strengthening drug already approved for osteoporosis, can reduce fractures in…

PREVENTABLE is a large Phase 4 trial testing whether atorvastatin 40 mg — a common cholesterol-lowering statin — can reduce the combined risk of death,…

This Phase 3 trial tested donanemab, an anti-amyloid antibody drug, against placebo in people with early Alzheimer's disease. Researchers measured how well it…

This trial tests donanemab, an anti-amyloid antibody given by infusion, against a placebo in people with no memory or thinking problems but signs of amyloid in…

This trial tests two investigational drugs, E2814 and lecanemab, in people who carry a gene mutation that causes early-onset Alzheimer's. It measures changes…

This trial is testing whether masupirdine, a daily pill, can ease agitation in people who already have Alzheimer's dementia. Agitation can mean restlessness,…

This Phase 3 trial is testing remternetug, an anti-amyloid antibody given by IV or injection under the skin, in people with early symptomatic Alzheimer's…

This Phase 3 trial is testing KarXT, an oral drug, to see whether it prevents the return of psychosis symptoms — hallucinations and delusions — in people who…

This trial is testing CT1812, an experimental drug, in people with early Alzheimer's disease — either mild cognitive impairment or mild dementia confirmed by…

This Phase 2 trial is testing remternetug, an anti-amyloid antibody given by injection, in people who carry a rare genetic mutation (in APP, PSEN1, or PSEN2)…

This study uses brain scans to look at the connections between nerve cells, called synapses, in people with well-controlled HIV and in people without HIV. It…

This trial is testing whether KarXT, a drug targeting certain brain receptors, is safe to take for up to a year in people who already have Alzheimer's-related…

This trial is testing MitoQ, a mitochondria-targeted antioxidant supplement, in older adults aged 65 to 80 who have slow walking speed and/or mild cognitive…

This Phase 2 trial is testing BMS-986446, an antibody designed to target a specific form of tau protein that builds up in Alzheimer's disease. Researchers want…

This trial is testing whether a drug called JNJ-64042056 can slow the spread of tau protein in the brain, measured by PET scan. It enrolls people who already…

This trial is testing a peer support program for people who become agitated in the emergency department. Trained peers work alongside the ER team to help calm…

This trial tests whether a daily pill called acoramidis can delay or prevent heart or nerve damage in people who carry an inherited TTR gene variant but have…

This trial is testing KarXT, an already-FDA-approved antipsychotic drug, as a treatment for hallucinations and delusions that sometimes develop in people who…

This Phase 2 trial is testing whether a drug called E2814, given alongside the already-known anti-amyloid drug lecanemab, can reduce a tau protein marker…

This trial tests remternetug, an anti-amyloid antibody drug, in people who carry a gene mutation that causes early-onset Alzheimer's and who still have normal…

This trial tests remternetug, an anti-amyloid antibody drug, against a placebo. It measures how long it takes for memory, thinking, or daily-function problems…

This trial tests whether buntanetap, a daily pill, slows memory and thinking decline and helps everyday function in adults 55 to 85 with early Alzheimer's. It…

This trial tests VY7523, an experimental drug, in people with early Alzheimer's disease. Researchers are mainly checking how safe it is at three rising doses…

This trial tests a mobile app called Tools for Coping with Cancer, delivered through the Calm Health platform, to see whether it reduces distress and improves…

This study looks at how live versus recorded music affects anxiety and brain-heart activity in people with early Alzheimer's, dementia, or MCI and their…

This trial tests a new PET scan radiotracer called [18F]3F4AP, which is designed to image myelin — the protective coating on nerve fibers. Researchers want to…

This trial is testing KarXT plus a new extended-release version called KarX-EC — a non-opioid, non-antipsychotic drug combination — to see whether it reduces…